BioSpace News Archive

IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its second quarter 2021 financial and operating results on Wednesday, August 4, 2021.

Metagenomi, a gene editing company with a versatile portfolio of next-generation tools that enable precise edits to in vivo and ex vivo applications, announced the appointment of Simon Harnest as Chief Investment Officer and SVP Strategy.

PolarityTE, Inc. announced final data from a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers with its investigational product SkinTE® plus standard of care vs SOC alone.

UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021, prior to the open of the market.

Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that it has strengthened its board of directors with the addition of Nagesh Mahanthappa Ph.D., M.B.A., and Valerie Odegard, Ph.D.

Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second quarter financial results on Monday, August 9, 2021.

Carlsmed, Inc., a commercial stage medical device technology company, is announcing today that it has partnered with the International Spine Study Group Foundation (ISSGF), the premier study group on adult spinal deformity, to collect data on surgical treatment with personalized interbody devices.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the company will initiate a Phase 3 development program for the new once-daily investigational triple combination of VX-121/tezacaftor/VX-561 (deutivacaftor) in the second half of 2021.

National Resilience, Inc. (Resilience) and bluebird bio, Inc. (NASDAQ: BLUE), today announced a strategic alliance aimed to accelerate the early research, development and delivery of cell therapies.

Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, announced that it will host a second quarter 2021 investor call on Wednesday, August 4, 2021 at 8:00 AM EDT to discuss financial results and provide a corporate update.